Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | ALB | P02768 | 3/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7154210 | 1.00 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1980249 | 1.00 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14580321 | 1.00 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL31662024 | 0.87 | LMNA (0.47) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL8644096 | 0.84 | LMNA (0.45) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1739891 | 0.81 | POLG (0.48) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4285392 | 0.81 | LMNA (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10510561 | 0.80 | HRAS (0.44) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10512002 | 0.80 | DUT (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10512094 | 0.78 | NLRP3 (0.44) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116536308-A | Sequencing sealant and application thereof | 深圳吉因加医学检验实验室 | 2023-08-04 | — | — | CN | claimed |
| US-9198893-B2 | Combination antitumor therapy | GALERA LABS, LLC (US) | 2015-12-01 | — | — | US | claimed |
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | LIAONING LIFENG SCIENT & TECHNOLOGY DEV COMPANY LTD (CN) | 2015-06-04 | — | — | US | claimed |
| US-8124613-B2 | Spirotropane compounds | VIROCHEM PHARMA INC. (CA) | 2012-02-28 | — | — | US | claimed |
| US-20110136756-A1 | COMBINATION ANTITUMOR THERAPY | BIOSSIL INC. (CA) | 2011-06-09 | — | — | US | claimed |
| US-20110105546-A1 | SPIROTROPANE COMPOUNDS | VIROCHEM PHARMA INC. (CA) | 2011-05-05 | — | — | US | claimed |
| EP-2296645-A2 | COMBINATION ANTITUMOR THERAPY | Kereos, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| EP-2257567-A1 | NOVEL 17 BETA LUPANE DERIVATIVES | Virochem Pharma Inc. (CA) | 2010-12-08 | — | — | EP | claimed |
| WO-2009143454-A2 | COMBINATION ANTITUMOR THERAPY | KEREOS, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| WO-2009100532-A1 | NOVEL 17ß LUPANE DERIVATIVES | VIROCHEM PHARMA INC. (CA) | 2009-08-20 | — | — | WO | claimed |
| EP-0261595-B1 | PHARMACEUTICAL COMPOSITION COMPRISING 2',3'-DIDEOXYCYTIDIN-2'-ENE(2',3'-DIDEHYDROCYTIDINE) FOR TREATING PATIENTS INFECTED WITH RETROVIRUS | YALE UNIVERSITY (US) | 1992-09-02 | — | — | EP | claimed |
| US-5116822-A | Therapeutic application of dideoxycytidinene | STICHTING REGA VZW (BE) | 1992-05-26 | — | — | US | claimed |
| US-5109016-A | Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1992-04-28 | — | — | US | claimed |
| US-5077280-A | Coadministering pyrimidine nucleoside and phosphorylase inhibitor to reduce toxicity of nuceloside | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1991-12-31 | — | — | US | claimed |
| WO-1991000867-A1 | 5'-DIPHOSPHOHEXOSE NUCLEOSIDE PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-01-24 | — | — | WO | claimed |
| US-4963533-A | TREATMENT OF AIDS AND AIDS RELATED DISEASES | STICHTING REGA VZW (REGA) (BE) | 1990-10-16 | — | — | US | claimed |
| WO-1989011277-A2 | PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0342422-A2 | Process for the preparation of 2',3'-dideoxynucleosides, and intermediates used therein | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-23 | — | — | EP | claimed |
| WO-1989009603-A1 | TREATMENT OF VIRAL INFECTIONS | BROWN UNIVERSITY RESEARCH FOUNDATION (US) | 1989-10-19 | — | — | WO | claimed |
| EP-0311100-A2 | Derivatives of dideoxycytidine, their preparation and pharmaceutical use | F. HOFFMANN-LA ROCHE AG (CH) | 1989-04-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150893-A1 | ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION | CYP11B1, CYP51A1, CYP11B2 | LMNA 2583/4885THRB 3962/4885MTOR 2878/4885 |
| US-20110136756-A1 | COMBINATION ANTITUMOR THERAPY | SOD3, SOD1, MCL1 | LMNA 3699/4885THRB 4054/4885MTOR 3542/4885 |
| US-20110105546-A1 | SPIROTROPANE COMPOUNDS | CCR5, CXCR1, CXCR2 | LMNA 2735/4885THRB 375/4885MTOR 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.